Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, S. C., Dobbs, H. J., Ebbs, S. R., Fallowfield, L. J., Bates, T., Baum, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968186/
https://www.ncbi.nlm.nih.gov/pubmed/8431375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968186/
https://www.ncbi.nlm.nih.gov/pubmed/8431375

Ejemplares similares